Sonolisib

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Sonolisib
Category Enzyme inhibitors
Catalog number BBF-03986
CAS 502632-66-8
Molecular Weight 525.59
Molecular Formula C29H35NO8
Purity >98%

Online Inquiry

Description

Sonolisib, also known as PX-866, is a small-molecule wortmannin analogue inhibitor of the alpha, gamma, and delta isoforms of phosphoinositide 3-kinase (PI3K) with potential antineoplastic activity. PI3K inhibitor PX-866 inhibits the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.

Specification

Synonyms PX-866; PX866; PX 866
Storage Store at -20°C (dark)
IUPAC Name [(3aR,6E,9S,9aR,10R,11aS)-6-[[bis(prop-2-enyl)amino]methylidene]-5-hydroxy-9-(methoxymethyl)-9a,11a-dimethyl-1,4,7-trioxo-2,3,3a,9,10,11-hexahydroindeno[4,5-h]isochromen-10-yl] acetate
Canonical SMILES CC(=O)OC1CC2(C(CCC2=O)C3=C1C4(C(OC(=O)C(=CN(CC=C)CC=C)C4=C(C3=O)O)COC)C)C
InChI InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18,4)13-19(37-16(3)31)24(22)29(23,5)21(15-36-6)38-27(17)35/h7-8,14,18-19,21,34H,1-2,9-13,15H2,3-6H3/b17-14+/t18-,19-,21+,28-,29-/m1/s1
InChI Key QIUASFSNWYMDFS-HTQCQMLJSA-N
Source Synthetic

Properties

Appearance Solid Powder
Application Potential anti-cancer agent
Antibiotic Activity Spectrum neoplastics (Tumor)
Boiling Point 651.4±55.0°C at 760 mmHg
Melting Point 102-107°C
Density 1.3±0.1 g/cm3
Solubility Soluble in DMSO

Reference Reading

1. New ultrasound observations of fetal anomalies in the second trimester
L M Hill Curr Opin Radiol . 1992 Apr;4(2):93-101.
Accurate prenatal diagnosis of fetal anomalies is essential for making decisions on pregnancy management options and for the determination of recurrence risk. However, the types of congenital anomalies that should be diagnosed using routine sonography are difficult to define. Factors that can affect the ultrasonographic detection of a particular congenital abnormality include equipment resolution, the time in gestation when the anomaly becomes apparent, and sonographer or sonolist experience. This review outlines the work that has been done over the past year to improve the detection rate of specific second trimester congenital malformations.

Recommended Products

Bio Calculators

  • Solution Dilution Calculator
  • Molecular Weight Calculator
  • Molarity Calculator
Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

Calculate
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
g/mol
g

Recently viewed products

Spiro[4.5]dec-7-ene-8-carboxylic acid, 9-hydroxy-1-(4-hydroxy-1,5-dimethylhexyl)-4-methyl-, methyl ester, [1R-[1α(1R*,4R*),4β,5β(S*)]]- | Fattiviracin FV-8 | Ixazomib Citrate | L-681176 | Roccellaric acid | Sonolisib

Online Inquiry

Verification code

USA

  • International : 
    US & Canada (Toll free):
  • Fax:
  • Email:

UK

  • Tel:
  • Email:

Copyright © 2024 BOC Sciences. All rights reserved.

cartIcon
Inquiry Basket
Loading ......
Delete selectedGo to checkout